Compare Centrus Energy Corp (LEU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Recursion Pharmaceuticals Inc — how do they compare? Centrus Energy Corp trades at $157.86 (market cap $3.08B), while Recursion Pharmaceuticals Inc trades at $2.93 (market cap $1.53B). The key difference: Centrus Energy Corp is far larger — about 2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| LEU | RXRX | |
|---|---|---|
Market Cap | $3.08B | $1.53B |
Sector | Energy | Health |
52-Week High | $436.00 | $6.79 |
52-Week Low | $146.61 | $2.84 |
Enterprise Value | $2.39B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $156.39, showing modest daily gains amid a bearish technical outlook. The company reported mixed quarterly earnings, with a recent beat in Q1 2026 but misses in prior quarters. Positive developments include a $1 billion+ DOE contract and inclusion in the S&P SmallCap 600, highlighting its strategic role in the U.S. nuclear fuel supply chain. Valuation ratios remain elevated, with a P/E of 56.75, while profitability metrics like a 13.4% net income margin reflect solid operational performance.
The outlook for LEU is cautiously optimistic, driven by government contracts and nuclear energy tailwinds, but high valuation and recent earnings volatility pose risks. Analyst consensus is mixed with a $223.14 price target, suggesting potential upside if execution improves. Key risks include dependency on federal contracts and competitive pressures in the uranium sector.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
